Phospho-p16-INK4A(S140) Antibody Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P42771 |
---|---|
Clone Names | 9062601 |
Gene ID | 1029 |
---|---|
Other Names | Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, Cyclin-dependent kinase 4 inhibitor A, CDK4I, Multiple tumor suppressor 1, MTS-1, p16-INK4a, p16-INK4, p16INK4A, CDKN2A, CDKN2, MTS1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP3183a was selected from the region of human Phospho-p16-INK4A-S140. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CDKN2A (HGNC:1787) |
---|---|
Synonyms | CDKN2, MTS1 |
Function | Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. |
Cellular Location | Cytoplasm. Nucleus |
Tissue Location | Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
p16-INK4A functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. This protein acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. The gene for this protein is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
References
Ausserlechner, M.J., et al., Leukemia 19(6):1051-1057 (2005).Kawamata, N., et al., Eur. J. Haematol. 74(5):424-429 (2005).Wang, J.L., et al., Mod. Pathol. 18(5):629-637 (2005).Kuroda, H., et al., Cancer Genet. Cytogenet. 158(2):172-179 (2005).Fu, G.H., et al., FEBS Lett. 579(10):2105-2110 (2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.